EN ▼
Favorites
My Favorites
View All
Market Cap Price 24h%

Disclaimer: Content does not constitute investment advice. Trading involves risks—please invest with caution!

Anthropic launches physical biology laboratory to advance AI-driven drug development

2026-09-18 20:16:12
Bookmark

文章要点

Anthropic 在旧金山湾区建立了一间湿实验室,用于开展实体生物学研究。该设施支持该公司超越传统药物开发的生命科学计划。公司以约 4 亿美元收购了 Coefficient Bio,并推出了 Claude Science 软件。CEO Dario Amodei 因父亲去世的个人经历,推动公司关注被忽视的疾病。尽管瞄准高达 2 万亿美元的 IPO,Anthropic 同时也引发了人们对人工智能相关危险的担忧。

战略采购与合作

Anthropic 在旧金山湾区悄然建立了一间湿实验室,将其生命科学的野心从计算机模拟转向实体生物实验。该公司通过其 Claude AI 模型获得知名度,并在本周早些时候接受路透社采访时承认了该湿实验室的存在。

ANTHROPIC 建立生物实验室以推动 AI 进入药物开发
Anthropic 已在湾区建立一间湿实验室,将其生命科学的野心从计算机模拟转向实体生物实验。
该公司希望 Claude 能够指导实验室机器人进行……
— *Walter Bloomberg (@DeItaone) 2026年9月18日

据 Anthropic 生命科学部门负责人 Eric Kauderer-Abrams 表示,该组织坚持认为,物理实验室实验仍然是生物研究的最终验证方法。一位公司代表澄清,该设施的用途不仅限于传统的药物开发,但未透露更多细节。

该公司一直对其解决大型制药公司忽视的医疗条件的雄心保持透明。Anthropic 旨在专注于那些缺乏商业吸引力的疾病,即主流制药厂商不愿涉足的领域。

在近期的一篇文章中,CEO Dario Amodei 分享了这一举措背后深刻的个人动机。他描述了自己如何在研究人员发现有效治疗手段前的几年里,目睹父亲因病去世的经历。

公司在生命科学领域的存在迅速扩张。Anthropic 通过股票交易完成了对 Coefficient Bio 的收购,交易价值接近 4 亿美元。此外,诺华(Novartis)首席执行官 Vas Narasimhan 加入其董事会,公司还发布了专门的平台 Claude Science。

目前的招聘工作反映了这一生物学重点。开放职位针对蛋白质和核酸分析专家,以及负责扩大采购和物流职能的运营负责人。

公司与主要制药企业保持着合作伙伴关系。Anthropic 目前向罗氏基因泰克(Genentech)、百时美施贵宝(Bristol Myers Squibb)和诺和诺德(Novo Nordisk)等机构提供 AI 能力和服务。

尽管拥有这些行业联系,Anthropic 澄清它不会直接参与药物商业化竞争。Kauderer-Abrams 强调,公司已设定明确界限,包括在此阶段避免执行临床试验。

在增长与谨慎之间 navigating 矛盾

Anthropic's pharmaceutical business is in a period of internal tension. Some company researchers have recently issued warnings that AI technology may pose a threat to human survival. The group also reported discovering potential applications for its systems in the creation of biological weapons, but these claims have been questioned externally.

CEO Dario Amodi has publicly advocated slowing the pace of AI development, pointing out the possibility that increasingly complex future systems could cause serious harm.

Meanwhile, the company is positioning itself for a public offering that analysts predict could be valued at US$2 trillion.

Kauderer-Abrams outlines Anthropic's vision to have Claude AI control experimental robotic laboratory systems with minimal human intervention. However, the company emphasized that human supervision remains crucial.

Alphabet's drug discovery division, Isomorphic Labs, has been conducting clinical trials for several years and recently postponed its schedule until the end of 2026. Anthropic has not yet attempted human trials.

In August this year, the company launched the Model Hardware Standard, which aims to promote the interaction between AI and laboratory instruments. In terms of staffing and capital allocation, life sciences have now become one of Anthropic's most significant commitments.

Limited time discount

Get 3 free stock e-books

Use expert analysis to discover top stocks that perform well in artificial intelligence, cryptocurrency and technology.

  • 前 10 大 AI 股票 - 领先的 AI 公司
  • 前 10 大加密股票 - 区块链领导者
  • 前 10 大科技股票 - 科技巨头

Disclaimer:

All content published on this website, including hyperlinks, related applications, forums, blogs, and other media accounts, originates from third-party platforms and their users. CoinMarketInsight makes no representations or warranties of any kind regarding the website or its content. All blockchain-related data and materials are provided for informational and research purposes only and do not constitute financial, legal, or investment advice. Users and third parties are solely responsible for the content they publish. CoinMarketInsight shall not be liable for any losses arising from the use of this website. You should exercise caution and conduct your own independent research, review, analysis, and verification before making any decisions.

Read Full Article
More News
Coinokc

Coinokc

Coinokc 2025 All Rights Reserved

Copyright(C) Coinokc.com, All Rights Reserved.

Guangdong ICP License No. 2025432472-2

sitemap

Disclaimer: All content posted on this website, hyperlinks, related applications, forums, blogs, and other media accounts, as well as on other platforms and by users, originates from third-party platforms and their users. Bishitong makes no guarantees of any kind regarding the website and its content. All blockchain-related data and other content materials on the website are solely for user learning and research purposes and do not constitute advice or basis for investment, legal, or any other fields. Any content posted on this website by Bishitong users or other third-party platforms is the responsibility of the individual posting and has nothing to do with Bishitong. Bishitong is not responsible for any losses incurred due to the use of information on this website. You are advised to use relevant data and content with caution and bear all risks arising therefrom. It is strongly recommended that you independently research, review, analyze, and verify the content.

Beware of the risk of illegal fundraising under the guise of "virtual currency" and "blockchain"